The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

A Winnipeg mother with a newborn is pleading with the province to start offering RSV shots to all babies. As we navigate ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.

Sanofi has added to its vaccine pipeline with an agreement ... It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia.

As RSV season ramps up, the American Lung Association is partnering with Sanofi to help educate parents and expectant ... infants and some young children at increased risk, and an RSV vaccine received ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Sanofi (SNY) announced Beyfortus will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon ...

This season will be the first time in Ontario that nirsevimab (sold under the brand name Beyfortus) is used to protect babies ...

While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...